Quick search:
Result Content Outlet Published Research
Result Content Outlet Published Research
1 New genetic clues on multiple sclerosis risk Science Daily 13 hours ago
2 Quanterix' Simoa® Technology Powers Latest Breakthrough in Epstein-Barr Virus and Multiple Sclerosis Business Wire 3 days ago
3 AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the French Health Authority (ANSM) Yahoo Finance 26 days ago
4 Janssen Showcases Recent Data in Relapsing Multiple Sclerosis at the 2021 European Committee for Treatment and Research in Multiple Sclerosis Congress PRNewswire 4 months ago
5 Updated MS Guidelines Advocate Earlier, More Aggressive Treatment Medscape 3 months ago
6 TG Therapeutics Announces Data for Ublituximab in Multiple GlobeNewswire 4 months ago
7 Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) GlobeNewswire 4 months ago
8 #ECTRIMS2021 – Real-world Data Support Mavenclad for Relapsing MS Multiple Sclerosis News Today 4 months ago
9 #ECTRIMS2021 – Quitting Smoking May Help Slow MS Progression Multiple Sclerosis News Today 4 months ago
10 Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis Yahoo Finance 4 months ago
11 #ECTRIMS2021 – For MS Disabilty, Ublituximab Is Better Than Aubagio Multiple Sclerosis News Today 3 months ago
12 Agreement of different OCT scan directions for individual retinal-layer thickness measurements in multiple sclerosis subjects with prior unilateral optic neuritis | Scientific Reports 17 days ago
13 Looking Beyond the Typical Measures of MS Diagnosis Medscape 3 months ago
14 Neurology Today LWW Journals 3 months ago
15 #ECTRIMS2021 ATA188 Benefits in SPMS, PPMS Hint at Remyelination 4 months ago
16 The News That Mattered in 2021: Neurology Today: Editorial... : Neurology Today LWW Journals 9 days ago
17 Serum Neurofilament Light Level May Predict MS Progression Medscape 3 months ago
18 ECTRIMS: Roche touts 8-year Ocrevus data to defend multiple sclerosis leadership FiercePharma 4 months ago
19 Sanofi tries to quiet naysayers with follow-up data on MS drug at heart of $3.7B Principia buyout FierceBiotech 4 months ago
20 Weed my lips: The good and not-so-good aspects of cannabis use among patients, part 2 RDH Magazine 10 days ago
21 Gene therapy of prostate cancer using liposomes containing perforin expression vector driven by the promoter of prostate-specific antigen gene | Scientific Reports 2 days ago
22 Teprotumumab Proves Efficacious for Proptosis in Thyroid Eye Disease Neurology Advisor 2 months ago
23 Which Agent Best for Neuromyelitis Optica? Medscape 3 months ago
24 Virtual Care May Help Multiple Sclerosis Patients Even After the Pandemic MedPage Today 4 months ago
25 Stem Cell Transplant Benefits in Secondary Progressive MS Medscape 3 months ago
26 2022 Orphan diseases outlook The Pharma Letter 4 days ago
27 Ofatumumab Safety Data Reinforced By Multi-Year Study in Patients With Relapsing Multiple Sclerosis Pharmacy Times 3 months ago
28 Frequent MRI May Spot Active Secondary Progressive MS More Quickly MedPage Today 3 months ago
29 What's good for the heart is good for the brain Science Daily 3 days ago
30 Year in Review: Multiple Sclerosis | MedPage Today MedPage Today 2 months ago
31 Clene Nanomedicine Presents Blinded Interim Update from GlobeNewswire 4 months ago
32 Biogen to face investors at JP Morgan healthcare conference Triangle Business Journal 23 days ago
33 Diroximel Fumarate (Vumerity) Cleared for MS in Europe Medscape 2 months ago
34 European Commission approves PONVORYTM (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features Business Wire 8 months ago
35 Rituximab More Effective Than Other MS Treatments? Medscape 4 months ago
36 The Pharma Letter Podcast — Episode 6 — Patient empowerment and multiple sclerosis The Pharma Letter 3 months ago
37 Positive safety data for long-term use of MS drug Kesimpta - pharmaphorum 4 months ago
38 Enspryng reduces relapse in NMOSD subgroup Healio 4 months ago
39 CNM-Au8 Seen to Raise Energy Metabolism of Brain in RRMS Trial Multiple Sclerosis News Today 6 months ago
40 The Latest on Multiple Sclerosis and COVID-19 Vaccines Medscape 4 months ago
41 Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress BioSpace 3 months ago
42 Amylyx Pharmaceuticals: Targeting Multiple Destructive Pathways To Reduce Neuronal Death Seeking Alpha 26 days ago
43 Atara Biotherapeutics: Developing personalized, off-the-shelf therapies for multiple sclerosis 5 months ago
44 BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS PRNewswire 4 months ago
45 ECTRIMS-ACTRIMS 2017 Medscape 4 years ago
46 New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis Yahoo Finance 4 months ago
47 CHMP Recommends VUMERITY® (diroximel fumarate) for Approval GlobeNewswire 4 months ago
48 TG Therapeutics Provides Business Update and Reports Third GlobeNewswire 3 months ago
49 MS News That Caught My Eye Last Week: Deep Brain Stimulation... Multiple Sclerosis News Today 4 months ago
50 Republicans Give Kristi Noem's Weird 'School Prayer Bill' a Big Nope Daily Beast 8 days ago
51 European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm 2 years ago
52 Thursday, January 27, 2022 Kaiser Health News 2 days ago
53 COVID-19 Risks No Higher in Patients With Multiple Sclerosis Medscape 1 year ago
54 Nanocrystals Boost Bioenergetics and Restore Neuronal Health Genetic Engineering & Biotechnology News 3 months ago
55 The Spectrum of Multiple Sclerosis will be the focus at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2021 Forum Newswise 1 year ago
56 More Results for Ozanimod: DAYBREAK Data, Cognition and Gray Matter, Biomarker for Relapsing MS Managed Markets Network 2 years ago
57 Ublituximab Under Review for Relapsing Forms of Multiple Sclerosis Monthly Prescribing Reference 2 months ago
58 Novartis study: Nurses and MS patients give thumbs-up to Kesimpta for ease of use FiercePharma 11 months ago
59 Rituximab Better Than Natalizumab for MS Relapses? Medscape 2 months ago
60 New Consensus Guideline on Clinical MRI Use in MS Medscape 3 months ago
61 Efficacy of Ofatumumab Greater than Teriflunomide in Early Relapsing MS Neurology Advisor 1 year ago
62 Ponesimod Shown Promising for MRI Outcomes in Relapsing MS Neurology Advisor 1 year ago
63 BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update PRNewswire 3 months ago
64 Janssen to Highlight Latest Research on Multiple Sclerosis at ACTRIMS Forum 2021 PRNewswire 11 months ago
65 Novartis receives positive CHMP opinion for Kesimpta®* GlobeNewswire 1 year ago
66 Cannabis Use Common for MS-Related Spasticity Medscape 3 months ago
67 MS Therapy Fampyra Not Eligible To Be Added to NHS for England: NICE Multiple Sclerosis News Today 1 month ago
68 ECTRIMS: Roche's Ocrevus, given early, cuts wheelchair risk by 42% FiercePharma 2 years ago
69 Euro Roundup: CHMP recommends drugs from Biogen and Roche, knocks back Pfizer filing Regulatory Focus 4 months ago
70 Multiple sclerosis and the COVID-19 vaccine: Safety and more Medical News Today 5 months ago
71 Lessons for Patients With MS and COVID-19 Medscape 1 year ago
72 Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress Business Wire 6 months ago
73 Determining SPMS as Biological Instead of Classification Managed Healthcare Executive 10 months ago
74 iMSMS Findings Offer Insight Into Gut Microbiome Involvement in MS Neurology Advisor 1 year ago
75 ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2021 GlobeNewswire 3 months ago
76 Rivka Galchen · Whack-a-Mole: Anti-Vax Sentiments · LRB 27 January 2022 London Review of Books 10 days ago
77 Janssen Announces US FDA Approval of PONVORY™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions PRNewswire 11 months ago
78 New Data Further Reinforce Genentech's Ocrevus (ocrelizumab) as a Highly Effective Treatment for People With Multiple Sclerosis BioSpace 1 year ago
79 SK channel activation alters peripheral metabolic pathways | JIR Dove Medical Press 7 days ago
80 Need to Know: What Is Acthar Gel? Multiple Sclerosis News Today 2 years ago
81 MS treatment a step closer after drug shown to repair nerve coating The Guardian 1 year ago
82 MS Society of Canada Urges Consistent Access to COVID-19 Boosters Multiple Sclerosis News Today 2 months ago
83 Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies The Lancet 4 months ago
84 Need to Know: What Are ACTRIMS and ECTRIMS? Multiple Sclerosis News Today 3 years ago
85 Sun Exposure Linked to Reduced Pediatric MS Risk Medscape 11 months ago
86 New Biogen Data Presented at ACTRIMS-ECTRIMS Advance GlobeNewswire 1 year ago
87 Link Between Lesion Location and Obstructive Sleep Apnea in Multiple Sclerosis Neurology Advisor 2 years ago
88 Convalescent plasma futile as treatment for critically ill COVID-19 patients, study finds Science Daily 4 months ago
89 Safety of the BNT162b2 COVID‐19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel Wiley 6 months ago
90 A Cheap Biotech Stock Tests a Novel Treatment for Multiple Sclerosis Barron's 2 years ago
91 New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and GlobeNewswire 1 year ago
92 Preferences for Multiple Sclerosis Treatments in the US | PPA Dove Medical Press 7 months ago
93 The Apparent Slowing of Disability Progression in Multiple Sclerosis Neurology Advisor 2 years ago
94 Safety Concern With Fingolimod to Ocrelizumab Switch in MS Medscape 1 year ago
95 PONVORY (ponesimod) for the Treatment of Multiple Sclerosis Clinical Trials Arena 10 months ago
96 Treatment Options Lacking in Primary Progressive Multiple Sclerosis Managed Markets Network 1 year ago
97 Janssen sends off NDA for new multiple sclerosis drug ponesimod FierceBiotech 2 years ago
98 Dr John Corboy on Research About Stopping Disease-Modifying Therapies for Multiple Sclerosis Managed Markets Network 1 year ago
99 Research shows race is a factor in disparities of symptom prevalence and response to treatment in multiple sclerosis treatment Newswise 10 months ago
100 Update on Regulatory Submission for Aducanumab in the European UnionBiogen to seek re-examination following CHMP negative opinion for aducanumab BioSpace 1 month ago